Liz Highleyman

Some countries have met or exceeded the 90-90-90 targets, but others are falling behind.

HIV-positive people who underwent surgery to remove early lung cancer fared as well as HIV-negative people.

After almost a decade on antiretroviral therapy, half of study participants still had HIV in immune cells in their brain and spinal fluid.

PrEP use increased across regions and demographic groups but remains lower among Black and Latino men.

Long-term salvage therapy without NRTIs suppressed HIV in nearly 80% of those who remained in care.

CDC experts recommend the vaccine for children, teens and HIV-positive people.

A third of mice treated with gene editing technique plus long-acting antiretrovirals showed no remaining traces of HIV.

Recommendations call for everyone to get tested at least once in their lifetime.

People living with HIV are also facing cancer as they age.

Continuum of care review finds 80% of transgender women in care achieve an undetectable viral load.

Study in China sees an association with several cancer types, especially gastrointestinal malignancies.

Interfering with this receptor on immune cells could have harmful health consequences.

Insurers must cover Truvada now that the U.S. Preventive Services Task Force gives it a Grade A recommendation.

Keytruda and Imfinzi were well tolerated and responses were similar to those seen in HIV-negative people.

A quarter of study participants accounted for three-quarters of newly diagnosed cases of chlamydia, gonorrhea and syphilis.